Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 26, Issue 1, Pages 25-33Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.10.009
Keywords
Psoriasis; TNF; Tumor necrosis factor; Type I interferons; IL-17/IL-23
Categories
Funding
- Agency for Innovation by Science and Technology (IWT) [101190]
- Research Foundation Flanders (FWO Vlaanderen) [1220613N, 12C8512N]
- Interuniversity Attraction Poles Program of the Belgian Science Policy (IUAP) [VII-32]
Ask authors/readers for more resources
Psoriasis is a skin disease where various cytokines play a detrimental role, yet our understanding of the disease is still limited. TNF is a validated drug target in psoriasis and other autoimmune diseases, but its use is associated with side effects. Some paradoxical side effects of anti-TNF treatment are supposedly associated with type I IFNs, which are also implicated in the pathogenesis of psoriasis. Recently, the IL-23/IL-17 axis has been associated with psoriasis as well, and new drugs targeting this axis have already been developed. Findings suggest that these cytokines are interwoven. We discuss recent findings reinforcing the role of TNF, Type I IFNs and IL-17 in the pathogenesis of psoriasis and the apparent inflammatory interplay between these three cytoldnes. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available